Related Experiment Video

Updated: Apr 28, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.1K

Cabozantinib for progressive metastatic medullary thyroid cancer: a review

Joshua R Colombo1, Richard O Wein1

  • 1Department of Otolaryngology, Head and Neck Surgery, Tufts Medical Center, Boston, MA, USA.

Therapeutics and Clinical Risk Management
|June 13, 2014
PubMed

Insights

Cabozantinib, a tyrosine kinase inhibitor, offers a new treatment for advanced medullary thyroid cancer. This drug shows promise for patients with progressive, metastatic disease, expanding therapeutic options.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Medullary thyroid cancer (MTC) is rare, often diagnosed at advanced stages.
  • Limited treatment options existed for progressive, metastatic MTC previously.

Purpose of the Study:

  • To review the clinical pharmacology, trial data, and safety of cabozantinib for MTC.
  • To discuss future directions in MTC treatment.

Main Methods:

  • Review of clinical pharmacology data.
  • Analysis of results from a large Phase III clinical trial.
  • Summary of safety data.

Main Results:

  • Cabozantinib, a tyrosine kinase inhibitor, demonstrated promising results in a Phase III trial.
  • The US Food and Drug Administration approved cabozantinib for MTC treatment.

Conclusions:

  • Cabozantinib represents a significant advancement in treating advanced MTC.
  • Further research may explore expanded applications and future therapies for MTC.
Keywords:
cabozantinibmedullary thyroid cancertyrosine kinase inhibitor

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

24.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K